Raptor Pharmaceutical (RPTP) continues to trade lower after the company reported late Thursday mixed financial results for Q4 and provided disappointing sales guidance for fiscal 2014.
Shares are now down 21.3% at $11.64, with a 52-week range of $5.40 – $17.72. IN Thursday’s after hours, shares were down about 12%.
The early development-stage company reported a Q4 loss of $0.19 per share, versus the Capital IQ consensus estimate of $0.18 loss per share. Product revenue from the company’s drug Procysbi, which is indicated for the management of nephropathic cystinosis in adults and children, were $10.2 million, versus the Street view of $9.02 million, if comparable.
The company expects Procysbi sales of $55 million – $65 million for fiscal 2014. The Street view is for total revenues of $68.84 million, so it’s not clear if that directly compares.
Suggested Reading: Best Finance Blogs